BofA analyst Kevin Fischbeck lowered the firm’s price target on Elevance Health (ELV) to $330 from $350 and keeps a Neutral rating on the shares. The market was bracing for a guidance cut at Elevance following news from peers Centene (CNC) and Molina Healthcare (MOH), but the magnitude of the cut was bigger than expected, the analyst tells investors. Such cuts often can be a clearing event, but the market had “more questions than answers” after learning that Q2 was weaker than it looked due to a one-time provider settlement and 2025 benefitted from lower taxes, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target lowered to $316 from $428 at Morgan Stanley
- ACA marketplace plans seek double digit rate increases for 2026, WSJ says
- Elevance Health price target lowered to $358 from $434 at Barclays
- U.S. Health insurers prescription drug denials on the rise, NYT says
- Elevance Health Reports Strong Revenue Growth in Q2 2025